Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Medspray has developed a proprietary micro-nozzle “soft mist” spray technology that enables highly efficient and gentle pulmonary or nasal drug delivery. Their platform allows improved lung deposition with less degradation of sensitive biologicals compared to traditional nebulizers. The company partners with pharma/biotech firms to enable new inhaled/nasal products—including fragile modalities like mRNA vaccines—and has licensed its tech to companies such as Silo Pharma (for intranasal PTSD therapy) and Resyca/Recipharm for advanced combination products[2][5][6].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Medspray.